Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigationsof late neuropsychologic effects

Citation
M. Stuschke et al., Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigationsof late neuropsychologic effects, J CL ONCOL, 17(9), 1999, pp. 2700-2709
Citations number
49
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
JOURNAL OF CLINICAL ONCOLOGY
ISSN journal
0732-183X → ACNP
Volume
17
Issue
9
Year of publication
1999
Pages
2700 - 2709
Database
ISI
SICI code
0732-183X(199909)17:9<2700:PCIILA>2.0.ZU;2-M
Abstract
Purpose: Relapse pattern and late toxicities in longterm survivors were ana lyzed after the introduction of prophylactic cranial irradiation (PCI) into a phase II trial on trimodality treatment of locally advanced (LAD) non-sm all-cell lung cancer (NSCLC). Patients and Methods: Seventy-five patients with stage IIIA(N2)/111B NSCLC were treated with induction chemotherapy preoperative radiochemotherapy, an d surgery. PCI was routinely offered during the second period of study accr ual. Patients were given a total radiation dose of 30 Gy (2 Gy per daily fr action) over a 3-week period starting 1 day after the last chemotherapy cyc le. Results: Introduction of PCI reduced the rate of brain metastases as first site of relapse from 30% to 8% at 4 years (P = .005) and that of overall br ain relapse from 54% to 13% (P < .0001). The effect of PCI was also observe d in the good-prognosis subgroup of 47 patients who had a partial response or complete response to induction chemotherapy, with a reduction of brain r elapse as first failure from 23% to 0% at 4 years (P = .01). Neurapsycholog ic testing revealed impairments in attention and visual memory in long-term survivors who received PCI as well as in those who did no, receive PCI. T2 -weighted magnetic resonance imaging revealed white matter abnormalities of higher grades in patients who received PCI than in those who did not. Conclusion: PCI at a moderate dose reduced brain metastases in LAD-NSCLC to a clinically significant extent, comparable to that in limited-disease sma ll-cell lung cancer. Late toxicity to normal brain was acceptable. This stu dy supports the use of PCI within intense protocols for LAD-NSCLC, particul arly in patients with favorable prognostic factors. (C) 1999 by American So ciety of Clinical Oncology.